cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Nur Samsu
Contact Email
crjim@ub.ac.id
Phone
+6281911005600
Journal Mail Official
crjim@ub.ac.id
Editorial Address
Jl. JA Suprapto No. 2 Kec. Klojen Malang 65112, Indonesia. Laboratory of Internal Medicine, Department of Internal Medicine, Faculty of Medicine, dr. Saiful Anwar General Hospital, IRNA 1 Building 2nd Floor
Location
Kota malang,
Jawa timur
INDONESIA
CRJIM (Clinical and Research Journal in Internal Medicine)
Published by Universitas Brawijaya
ISSN : 27235130     EISSN : 27235122     DOI : https://doi.org/10.21776/ub.crjim
Core Subject : Health, Science, Education,
Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other
Clinical and Research Journal in Internal Medicine is the official open access journal of Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. It publishes articles two times per year. It is a peer reviewed publication of Indonesian Internal Medicine journals and accepting articles for publication from around the world. CRJIM only publishes articles in the English version. The objective of this journal is to publish the selected clinical and basic research relevant to Internal Medicine. It covers the following topics, nephrology, endocrinology, metabolic, and diabetes, rheumatology, geriatrics, tropic infection, hematology oncology. CRJIM publishes original researches, reviews, brief reports, editorial, case series, case reports, and commentary. Additionally, it also considers publishing animal studies relevant to Internal Medicine topic. It is an international journal dedicated to providing new information that could give new insight for alternative solutions, diagnosis, therapy and prevention for researchers and practitioners in Internal Medicine.
Arjuna Subject : Kedokteran - Kedokteran Internal
Articles 7 Documents
 1 
Search results for , issue "Vol 2, No 1 (2021): First Issue of 2021" : 7 Documents clear
Challenges in Diagnostic and Management of Nephritic Syndrome in Diabetic Nephropathy Patient: a Case Report Novitasari, Adinda Dian; Samsu, Nur
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.7

Abstract

The clinical presentation of patients with acute glomerulonephritis (GN) varies widely, from asymptomatic to clinical presentations of acute kidney injury (AKI), edema, and hypertension. Diagnosis of GN in patients with diabetic nephropathy (DN) is a challenge due to pre-existing edema, hypertension, and decreased renal function. Likewise in terms of management of steroid immunosuppressants related to blood sugar regulation. It has been reported that 35-year-old male patients with diabetes mellitus (DM) with DN whose kidney function deteriorated rapidly. The patient complained of cola-red urine and decreased urine volume the day before admission. Physical examination showed blood pressure of 160/95 mmHg, bilateral leg edema, active chronic ulcer in the left lower leg, hemoglobin level was 8.7 g / dl, leukocytes 17.400 / ul, serum urea level 96 mg / dl, serum creatinine level 7.01 mg / dl, ASTO titer + 800 IU / ml, macroscopic hematuria, and albuminuria +4 on urinalysis. Ultrasonography revealed enlarged kidney size and signs of acute renal inflammation. Based on these data the patient was diagnosed clinically as rapidly progressive GN due to post-infectious GN. The patient received 3 days of pulse methyl prednisolone therapy continued orally, blood sugar regulation with insulin, RAS blockers, intravenous antibiotics and ulcer debridement. After 1 week of therapy, clinical and laboratory improvements were found and at the next follow-up renal function returned to baseline about 2 weeks later.
The Duration of Hemodialysis and its Implication to Barthel Score and Laboratory Parameters among End Stage Renal Disease Patients Jahidi, Savero Mizan; Mardiana, Nunuk; Wardhani, Indrayuni Lukitra
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.3

Abstract

Background: While it was proven that hemodialysis for treating patients with end stage renal disease (ESRD) provided the reduced mortality rate, the reports on its adequacy in the context of laboratory parameters and psychological function were limited. Aim: To assess the implication of hemodialysis duration on Barthel score and laboratory parameters among ESRD patients.  Methods: During the period, a cross-sectional study was conducted at Dr. Soetomo General Hospital. Information related to age, gender, history of hypertension, history of diabetes mellitus, and the levels of hemoglobin, albumin, calcium, and phosphor were retrieved from medical records. While, we performed the interview to each participant using Barthel index questionnaire to assess the function independence. We used multiple logistic regression analysis to determine the correlation and estimate of effect. Results: We totally include we included 65 patients with the hemodialysis duration of more than one year and 16 patients with the hemodialysis duration of less than one year. Our results found that the higher levels of albumin and hemoglobin were observed in patients with hemodialysis duration of more than one year. While, the duration of hemodialysis did not affect the Barthel score and serum mineral parameters. Conclusion:  The duration of hemodialysis of more than one year is associated with the improvement of albumin and hemoglobin levels
Shorter All-oral Bedaquiline-containing MDR-TB Regimen : The Backgrounds & Implementations Winoto, Eden Suryoiman; Candradikusuma, Didi
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.6

Abstract

The continuing spread of Multidrug-Resistant Tuberculosis (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, become one of the most urgent and difficult challenges in TB control. In Indonesia, the estimated total DR-TB case incidence of 24,000 or 8.8/100,000 population (2.4% of total new TB patients). The first-ever MDR-TB treatment guideline published by WHO required a long duration (up to 20–24 months) and contained toxic second-line drugs with less effective & unfavorable outcomes. About ten years ago, a short regimen lasting nine instead of 20 months, called “Bangladesh regimen”, revolutionized MDR-TB treatment. The advent of rapid molecular diagnostic tests, discoveries of new and repurposed drugs, promising results based on trials and meta-analysis had prompted WHO to update its guidelines. Notably, drugs such as bedaquiline and clofazimine are now strongly recommended for the treatment of MDR-TB. At the same time, older injectables drugs have been downgraded due to poor effectiveness and side-effect profiles. In 2019, based on the programmatic data from the shorter all-oral bedaquiline-containing regimen implemented routinely in South Africa, WHO revised its recommendations on the use of a standardized shorter regimen. Based on the analysis, WHO affirmed its conditional recommendation for the shorter all-oral bedaquiline-containing MDR -TB regimen to be offered as a treatment option to MDR -TB patients who satisfy the eligibility criteria. The implementation of this all-oral shorter regimen is expected to improve the programmatic management of the MDR-TB worldwide.
Relationship between Disease Activity and Calcium Levels with Bone Mineral Density in Rheumatoid Arthritis Patients Megawanto, Nur Handy; Suryana, Bagus Putu Putra; Rosandi, Rulli
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.2

Abstract

Background: Arthritis rheumatoid (AR) is a chronic inflammatory disease that mainly affects the joints. Decreased bone mass and osteoporosis are its complications. Several factors such as dietary calcium, disease activity, physical activity, vitamin D levels, steroids can affect bone mineral density values. Aim: The purpose of this study was to determine the relationship between disease activity, calcium levels and bone mineral densitometry in patients with arthritis rheumatoid. Methods: 23 AR patients based on the 2010 ACR criteria including the inclusion criteria with a cross sectional study approach that had bone mineral densitometry (BMD) data for the last 1 year. Blood samples were also taken to check the total calcium level, the characteristics of the baseline data were collected, and the disease activity was examined using the DAS 28 LED. The relationship between these factors and the bone mass density was analyzed using the Spearman test. The analysis result was considered significant if p <0.05. Results: The results showed that the basic characteristics of the subjects were 45,87 years old, body mass index 24,51 kg / m2, duration of illness 3,96 years, steroid dose 3,48 mg, disease activity 4.35 (moderate disease activity), anti CCP 333,87 U / ml, rheumatoid factor (RF) 10,18 IU / ml, methotrexate 12,17 mg, leflunomide 20 mg. There was no significant relationship between serum calcium levels and disease activity with BMD. However, there was a significant relationship between age and BMI with BMD in the femur neck (p = 0,043), lumbar 3 (p = 0,017) and lumbar 4 (p = 0,048). Conclusion: There is no relationship between disease activity and calcium levels with bone mass density values in AR patients except for age and BMI.
Inflammation, Chronic Diseases and “Bone Quality” Rahman, Perdana Aditya
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.1

Abstract

Inflammation, Chronic Diseases and “Bone Quality”
Comparison of HBV DNA Quantitative Log in Patients Hepatitis B with Telbivudine Therapy Compared with Tenofovir Therapy in Saiful Anwar General Hospital Malang: January 2016 - December 2017 Nasution, Muhammad Imanuddin; Mustika, Syifa
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.5

Abstract

Background: Hepatitis B is a health problem with high endemic in Indonesia. Hepatitis B virus infection is transmitted parenterally, has a risk of liver cirrhosis and hepatocellular carcinoma. Detection and quantification of HBV DNA are markers of active HBV replication and determine treatment options for hepatitis B. Methods: compare log reduction of HBV DNA in patients treated with Telbivudine and Tenofovir. Results: There was no significant difference in HBV DNA levels between before and after Tenofovir treatment, namely 6 months follow-up (OR 95% CI = 5.41 [0.83 - 35.16], p = 0.0770) and 12 months (OR 95% CI = 5.39 [0.83 - 34.99], p = 0.0780). Telbivudine administration showed a significant difference in HBV DNA levels between before and after treatment at 6 months follow-up (OR 95% CI = 13.69 [4.53 - 41.40], p = 0.0001) and 12 months (OR 95% CI = 13.69 [ 4.53 - 41.41], p = 0.0001). Comparison of Tenofovir and Telbivudine therapy showed no significant difference at 6 months follow-up (OR 95% CI = 0.44 [0.10 - 1.88], p = 0.2690) but significant at 12 months follow-up (OR 95% CI = 6.23). [1.39 - 27.97], p = 0.0170). Conclusion:  There was a significant difference between the administration of Telbivudine as a treatment for hepatitis B with lower serum HBV DNA levels compared with the administration of Tenofovir at 12-month follow-up therapy.
Allium Sativum As Antimalaria Agent Via Falciapin Protease-2 Inhibitor Mechanism : Molecular Docking Perspective Syaban, Mokhamad Fahmi Rizki; Rachman, Hafidh Alyza; Arrahman, Azmirfani Diti; Hudayana, Nur; Khamid, Jaya Purna; Pratama, Farhan Adi
Clinical and Research Journal in Internal Medicine Vol 2, No 1 (2021): First Issue of 2021
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2021.002.01.4

Abstract

Background: Malaria is an endemic disease that can lead to death. Malaria control is a threatening cause of resistance to antimalarial drugs so that renewable therapies are needed to overcome this disease. The chemical compounds of garlic have potential as antimalarial agents, but the mechanism is still unknown. Aim: This research will predict the compounds' molecular mechanism in garlic (Allium sativum) using the in-silico method. Methods: The In-silico method using chemical compounds in Allium sativum were obtained from PubChem, and Falciapain protease-2 was obtained from the Protein Data Bank. Then performed a docking simulation between ligand-protein and analyzed it in 3D. We were used PyRx, Pymol, and DS (Discover Studio) software for analysis and visualization of the interaction of ligand-protein. Results: The results we got, the Alliin compound contained in Allium sativum has the strongest bond with Falcipain protease-2. Allin has fulfilled Lipinski Rule, so Alliin drug-likeness potentially. Alliin has antimalarial activity with its inhibition mechanism against Falcipain protease-2. Conclusion:  We recommend this study as a reference for further research on Aliin compounds as antimalarials through in vitro and in vivo methods.

Page 1 of 1 | Total Record : 7

 1 

Filter by Year

2021 2021


Reset
Filter By Issues
All Issue Vol. 6 No. 2 (2025): Volume 6 No 2, November 2025 Vol. 6 No. 1 (2025): Volume 6 No 1, May 2025 Vol. 5 No. 2 (2024): Volume 5 No 2, November 2024 Vol. 5 No. 1 (2024): Volume 5 No 1, May 2024 Vol. 4 No. 2 (2023): Volume 4 No 2, November 2023 Vol. 4 No. 1 (2023): Volume 4 No 1, May 2023 Vol. 3 No. 2 (2022): November 2022 Vol. 3 No. 1 (2022): The First Issue of Third Year Vol 2, No 1 (2021): First Issue of 2021 Vol 1, No 2 (2020): New: The Second Issue is Coming! Vol 1, No 1 (2020): New: The First Volume of Clinical and Research Journal in Internal Medicine More Issue